SG11201701875YA - Methods for detecting ovarian cancer - Google Patents
Methods for detecting ovarian cancerInfo
- Publication number
- SG11201701875YA SG11201701875YA SG11201701875YA SG11201701875YA SG11201701875YA SG 11201701875Y A SG11201701875Y A SG 11201701875YA SG 11201701875Y A SG11201701875Y A SG 11201701875YA SG 11201701875Y A SG11201701875Y A SG 11201701875YA SG 11201701875Y A SG11201701875Y A SG 11201701875YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- ovarian cancer
- detecting ovarian
- detecting
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20145855 | 2014-10-02 | ||
PCT/FI2015/050654 WO2016051020A1 (en) | 2014-10-02 | 2015-10-02 | Methods for detecting ovarian cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701875YA true SG11201701875YA (en) | 2017-04-27 |
Family
ID=55629471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701875YA SG11201701875YA (en) | 2014-10-02 | 2015-10-02 | Methods for detecting ovarian cancer |
Country Status (10)
Country | Link |
---|---|
US (1) | US10534001B2 (en) |
EP (1) | EP3201623B1 (en) |
JP (1) | JP6892820B2 (en) |
KR (1) | KR20170061704A (en) |
CN (1) | CN106716127B (en) |
AU (1) | AU2015326756A1 (en) |
BR (1) | BR112017006593A2 (en) |
CA (1) | CA2959832A1 (en) |
SG (1) | SG11201701875YA (en) |
WO (1) | WO2016051020A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3351938A1 (en) * | 2017-01-18 | 2018-07-25 | BIOCRATES Life Sciences AG | New biomarkers for assessing ovarian cancer |
US20210405054A1 (en) | 2017-07-05 | 2021-12-30 | Zora Biosciences Oy | Methods for detecting ovarian cancer |
CN107656006A (en) * | 2017-09-08 | 2018-02-02 | 上海市东方医院 | For detecting the kit and method of alpha hydroxyl butyric concentration in serum or blood plasma |
CN108152430A (en) * | 2017-12-21 | 2018-06-12 | 上海中科新生命生物科技有限公司 | Oophoroma marker detection kit and detection method based on PRM detections |
CN111430030A (en) * | 2020-04-17 | 2020-07-17 | 武汉大学 | Application method and system of biomarker in ovarian cancer assessment |
CN114544848B (en) * | 2020-11-25 | 2023-04-28 | 中国科学院大连化学物理研究所 | Serum lipid marker composition for diagnosing ovarian epithelial cancer, kit and application thereof |
EP4246146A1 (en) * | 2022-03-14 | 2023-09-20 | Fundació Institut Mar d'Investigacions Mèdiques (IMIM) | Method for diagnosing cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824555A (en) | 1996-05-30 | 1998-10-20 | The Cleveland Clinic Foundation | Method of detecting gynecological carcinomas |
US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
US20030180953A1 (en) * | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
WO2003015436A1 (en) * | 2001-08-10 | 2003-02-20 | Siemens Aktiengesellschaft | Method for fast and local error correction in the event of the failure of individual physical connections in bundled communication connections and communication system device for carrying out the method |
US20040180387A1 (en) * | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
US20050170441A1 (en) | 2003-09-12 | 2005-08-04 | Health Research, Inc. | Early detection of cancer of specific type using 1HNMR metabonomics |
WO2009052186A1 (en) | 2007-10-15 | 2009-04-23 | Georgia Tech Research Corporation | Metabolomics-based identification of disease-causing agents |
US8039668B2 (en) * | 2008-10-17 | 2011-10-18 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
GB2469244A (en) | 2008-01-28 | 2010-10-06 | Univ Singapore | Lipid tumour profile |
US20120004854A1 (en) | 2008-05-28 | 2012-01-05 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
JP4744618B2 (en) * | 2009-04-13 | 2011-08-10 | シャープ株式会社 | Gas component detector |
US20120197539A1 (en) * | 2009-10-09 | 2012-08-02 | Carolyn Slupsky | Methods for diagnosis, treatment and monitoring of patient health using metabolomics |
US20110114511A1 (en) * | 2009-11-17 | 2011-05-19 | Sjong Angele | Apparatus for detecting volatile organic compounds and related methods |
GB201016139D0 (en) | 2010-09-24 | 2010-11-10 | Univ Leuven Kath | Cancer phosholipidome |
FI20115576A0 (en) * | 2011-06-10 | 2011-06-10 | Teknologian Tutkimuskeskus Vtt Oy | A method for diagnosing Alzheimer's disease |
US20140156573A1 (en) | 2011-07-27 | 2014-06-05 | The Research Foundation Of State University Of New York | Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc |
-
2015
- 2015-10-02 US US15/513,755 patent/US10534001B2/en active Active
- 2015-10-02 SG SG11201701875YA patent/SG11201701875YA/en unknown
- 2015-10-02 BR BR112017006593A patent/BR112017006593A2/en not_active Application Discontinuation
- 2015-10-02 AU AU2015326756A patent/AU2015326756A1/en not_active Abandoned
- 2015-10-02 CA CA2959832A patent/CA2959832A1/en not_active Abandoned
- 2015-10-02 JP JP2017516994A patent/JP6892820B2/en active Active
- 2015-10-02 EP EP15846140.0A patent/EP3201623B1/en active Active
- 2015-10-02 WO PCT/FI2015/050654 patent/WO2016051020A1/en active Application Filing
- 2015-10-02 CN CN201580052938.0A patent/CN106716127B/en active Active
- 2015-10-02 KR KR1020177011691A patent/KR20170061704A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2959832A1 (en) | 2016-04-07 |
EP3201623A1 (en) | 2017-08-09 |
US20170285036A1 (en) | 2017-10-05 |
JP6892820B2 (en) | 2021-06-23 |
EP3201623A4 (en) | 2018-07-25 |
US10534001B2 (en) | 2020-01-14 |
JP2017535756A (en) | 2017-11-30 |
AU2015326756A1 (en) | 2017-05-11 |
EP3201623B1 (en) | 2020-07-22 |
KR20170061704A (en) | 2017-06-05 |
WO2016051020A1 (en) | 2016-04-07 |
BR112017006593A2 (en) | 2017-12-19 |
CN106716127A (en) | 2017-05-24 |
CN106716127B (en) | 2020-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201605660B (en) | Multispecific antibodies | |
PL3227332T3 (en) | Multispecific antibodies | |
GB201414823D0 (en) | Multispecific antibodies | |
GB201403489D0 (en) | Biomarkers for endometriosis | |
HK1231559A1 (en) | Method for detecting a solid tumor cancer | |
GB201408100D0 (en) | Detection method | |
SG11201609350XA (en) | Methods for inhibiting necroptosis | |
GB201405151D0 (en) | Improved luggage apparatus | |
SG11201701875YA (en) | Methods for detecting ovarian cancer | |
GB201420842D0 (en) | Detector | |
IL246558A0 (en) | Novel methods for treating cancer | |
GB201405203D0 (en) | Detecting apparatus | |
HK1231405A1 (en) | Methods and compositions for screening and detecting cancer | |
GB201419330D0 (en) | Detection method | |
IL257514A (en) | Cancer detection method | |
GB201416015D0 (en) | Biomarker | |
GB201411568D0 (en) | Detection | |
IL247270B (en) | Method of detecting cancer | |
SG11201702077RA (en) | Kit for cancer detection | |
GB201508480D0 (en) | Cancer | |
GB2537723B (en) | Apparatus for detecting approaching objects | |
GB201420239D0 (en) | Biomarker | |
GB201416459D0 (en) | Detection method | |
GB201402174D0 (en) | Detection method | |
GB201604813D0 (en) | Methods for detecting cancer |